Source comparison
TB-500 Post-Surgery Protocol Comparison
Minor soft tissue (arthroscopy, laparoscopic) 2mg twice weekly 4 weeks 16mg Adequate for procedures with minimal fascial disruption; extends proliferative phase without overshooting remodeling timeline Moderate orthopedic (ORIF, ligament repair) 2.5mg twice we
This comparison does not assign a generated winner or score.
- Minor soft tissue (arthroscopy, laparoscopic)
- 2mg twice weekly
- 4 weeks
- 16mg
- Adequate for procedures with minimal fascial disruption; extends proliferative phase without overshooting remodeling timeline
- Moderate orthopedic (ORIF, ligament repair)
- 2.5mg twice weekly
- 6 weeks
- 30mg
- Higher dose compensates for bone-tendon interface healing, which requires sustained angiogenesis beyond soft tissue alone
- Major reconstructive (abdominal, spinal fusion)
- 8 weeks
- 40mg
- Extended duration aligns with slower fascial and deep tissue remodeling; tapering in final 2 weeks optional based on clinical response
- Cosmetic (facelift, rhinoplasty)
- Lower inflammatory burden justifies shorter protocol; aesthetic outcomes prioritize collagen organization over rapid closure